First Wave BioPharma, Inc.’s improved formulation of its lead candidate adrulipase has disappointed in a Phase IIb trial of patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), rendering its future as a monotherapy uncertain in the roughly $2.2bn market.
First Wave’s Adrulipase Disappoints In Third Phase II CF EPI Trial Despite New Formulation
Stock Down By 39%
The US firm’s lead gastrointestinal asset has missed the mark in a mid-stage exocrine pancreatic insufficiency trial in cystic fibrosis patients despite its best efforts to enhance the formulation after two prior setbacks.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.